Murat Sarı

Ihlas Marmara Evleri - I. Kisim, 34899, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Integrated Prognostic Stratification After Perioperative FLOT in Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicenter Real-World Study.

Integrated Prognostic Stratification After Perioperative FLOT in Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicenter Real-World Study.

Journal: Journal of clinical medicine

Published: July 06, 2026

Efficacy and safety of sacituzumab govitecan in hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Efficacy and safety of sacituzumab govitecan in hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 19, 2026

Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.

Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.

Journal: Current oncology (Toronto, Ont.)

Published: June 18, 2026

Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study.

Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study.

Journal: Annals of Saudi medicine

Published: June 07, 2026

Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies.

Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies.

Journal: Journal of clinical medicine

Published: May 17, 2026

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: May 09, 2026

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Journal: Immunotherapy

Published: April 21, 2026

Acquired CD74-ROS1 fusion-mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report.

Acquired CD74-ROS1 fusion-mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report.

Journal: Journal of chemotherapy (Florence, Italy)

Published: April 17, 2026

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

Journal: Medicina (Kaunas, Lithuania)

Published: April 15, 2026

Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature.

Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature.

Journal: Current medical research and opinion

Published: February 17, 2026

Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.

Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.

Journal: Breast cancer (Dove Medical Press)

Published: January 24, 2026

Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

Journal: Medicina (Kaunas, Lithuania)

Published: January 10, 2026

Showing 1-12 of 41

Last Updated: 09/26/2026